Sepset Biosciences Inc., a spin-off company by The Centre for Drug Research and Development (CDRD), in collaboration with Dr. Robert Hancock, Professor of Microbiology and Immunology and Director of the Centre for Microbial Diseases and Immunity Research at the University of British Columbia, is developing a first in class diagnostic assay for the early and rapid diagnosis of sepsis. This unique diagnostic is based on the detection of a unique signature of sepsis based on the immune response rather than the presences of a pathogen.
This novel technology represent tremendous commercial potential as sepsis is one of the most expensive conditions for hospitals to treat and current methods of diagnosis (including blood cultures) can take over 24 hours and are not fully predictive. For every one-hour delay in diagnosis, the rate of mortality grows by eight percent. .
For more information, please contact:.Jonathon Jafari